基于BET抑制剂的组合,针对MECOM重新安排的 (r) AML中的新型依赖性
Christine E Birdwell1, Warren Fiskus1, Christopher P Mill1
1The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
Leukemia
|December 19, 2025
概括
在急性髓性白血病 (AML) 中的MECOM重组驱动了疾病的攻击性. 将BET抑制剂与PI3K/mTOR或IAP抑制剂相结合,在MECOM重排的AML模型中显示出更高的疗效.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 在AML中,MECOM重新排列,涉及inv(3) 或t(3;3),导致EVI1过度表达和GATA2抑制.
- 这种基因变异促进了激进的AML表型和对治疗的抗性.
- BET蛋白抑制剂 (BETi) 在MECOM重组的AML中显示出有效性.
研究的目的:
- 确定MECOM重新安排的AML中的新型治疗漏洞.
- 评估BET抑制剂与其他向药物的联合疗效.
主要方法:
- 高通量药物查以确定MECOM重排的AML细胞中的依赖性.
- 试验室药物敏感性测定与单疗法和组合治疗.
- 通过RNA-Seq,质谱学,CyTOF和西方斑点分析.
- 在MECOM重新安排的AML患者衍生异种移植 (PDX) 模型的体内疗效评估.
主要成果:
- 药物查发现了BRD4,PIK3CA,mTOR,BCL-xL和XIAP作为依赖性.
- 米韦布雷西布 (BETi),达克托利西布 (PI3K/mTOR抑制剂) 和LCL161 (IAP抑制剂) 在MECOM重新安排的AML中显示了剂量依赖的致命性.
- 米韦布雷西布与达克托利西布或LCL161协同诱导的亡的组合.
- 在PDX模型中,组合疗法减少了AML负担,改善了生存率.
结论:
- 与PI3K/mTOR或IAP抑制剂相结合的BET抑制剂对MECOM重组的AML具有更高的疗效.
- 这些发现支持进一步临床评估基于BETi的组合疗法,用于MECOM重新安排的AML.
相关概念视频
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K


